Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | NCF1 | P14598 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.34 |
| ▸ | LDHA | P00338 | 1/20 | 0.34 |
| ▸ | IP6K1 | Q92551 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9327541 | 0.93 | SMN1; SMN2 (0.39) | UTS2RALDH1A1KDM4ESMN1; SMN2ADRA1A | |
| SCHEMBL9011952 | 0.89 | UTS2R (0.37) | UTS2RADRA1A | |
| SCHEMBL9012300 | 0.89 | KDM4E (0.32) | UTS2RALDH1A1KDM4ESMN1; SMN2HSD17B10 | |
| SCHEMBL9012178 | 0.85 | ADRA1D (0.34) | UTS2RALDH1A1KDM4ESMN1; SMN2NCF1 | |
| SCHEMBL9329176 | 0.84 | ADRA1D (0.40) | UTS2RALDH1A1KDM4ESMN1; SMN2CYP1A2 | |
| SCHEMBL9011902 | 0.84 | AR (0.36) | SMN1; SMN2ADRA1AKMT2A | |
| SCHEMBL9012211 | 0.83 | TAAR1 (0.38) | UTS2RALDH1A1KDM4ESMN1; SMN2NCF1 | |
| SCHEMBL9012312 | 0.81 | — | — | |
| SCHEMBL9012162 | 0.81 | TAAR1 (0.35) | ADRA1A | |
| SCHEMBL6528639 | 0.81 | IDO1 (0.33) | ADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | claimed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | claimed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | claimed |
| JP-3163065-A | — | — | None | — | — | JP | disclosed |
| US-6906078-B2 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | PHARMACIA CORPORATION (US) | 2005-06-14 | — | — | US | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5523317-A | ADMINISTERING IMIDAZOLE DERIVATIVE | NIPPON CHEMIPHAR CO., LTD. (JP) | 1996-06-04 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0633026-A1 | Use of imidazole derivative for antihypertensive agent | NIPPON CHEMIPHAR CO., LTD. (JP) | 1995-01-11 | — | — | EP | disclosed |
| EP-0412529-B1 | Imidazole derivatives, process for the preparation of the same and antiulcer agents containing the same | NIPPON CHEMIPHAR CO (JP) | 1994-03-09 | — | — | EP | disclosed |
| EP-0584588-A1 | Anti-ulcer composition containing imidazole derivative | NIPPON CHEMIPHAR CO., LTD. (JP) | 1994-03-02 | — | — | EP | disclosed |
| US-5091403-A | SULFINYL IMIDAZOLE DERIVATIVES AND ANTIULCER AGENTS CONTAINING THE SAME | NIPPON CHEMIPHAR CO., LTD. (JP) | 1992-02-25 | — | — | US | disclosed |
| JP-H03163065-A | IMIDAZOLE DERIVATIVE, PRODUCTION THEREOF AND ANTIULCER AGENT CONTAINING SAME COMPOUND | NIPPON CHEMIPHAR CO LTD | 1991-07-15 | — | — | JP | disclosed |
| EP-0412529-A1 | Imidazole derivatives, process for the preparation of the same and antiulcer agents containing the same | NIPPON CHEMIPHAR CO., LTD. (JP) | 1991-02-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | UTS2R 3445/4885ALDH1A1 2148/4885KDM4E 1518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.